Biomarker Discovery & Validation

News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.

Nov 8, 2022

SimBioSys Gets $2M NCI Award for Tumor Visualization, Analysis Platform

Nov 1, 2022

OncoPrecision Validating Patient-Derived Functional Drug Screening Platform

Oct 25, 2022

ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia

Oct 21, 2022

PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests
Premium

Oct 20, 2022

GE Healthcare Educating Docs on Guidelines-Backed Use of Imaging Agent for ER-Positive Breast Cancer
Premium

Oct 13, 2022

Tavros Therapeutics, Bayer Subsidiary Vividion Ink Precision Oncology Deal

Oct 11, 2022

ONI, UPenn Partner on Microscopy-Based CAR T-Cell Therapy Biomarker Research

Oct 7, 2022

Swiss Biotech PreComb Therapeutics Wants to Automate Functional Precision Medicine
Premium

Sep 28, 2022

Cleara Biotech Raises $2.5M to Advance Cancer Drugs Targeting 'Scarred Cell' Biomarkers

Sep 20, 2022

Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis
Premium

Aug 24, 2022

MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape
Premium

Aug 5, 2022

Baylor College of Medicine Receives $5.5M NCI Grant for Several Liver Cancer Prevention Projects

Aug 2, 2022

Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies

Jul 14, 2022

Nilogen Oncosystems, Scailyte Partner to Improve Precision Cancer Drug Development

Jul 13, 2022

Nucleai, Sirona Dx Partner on Cancer Biomarker Discovery

Jun 10, 2022

Telix Pharmaceuticals, RefleXion Medical to Develop Illuccix-Guided Radiotherapy for Prostate Cancer

Jun 4, 2022

At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment
Premium

Jun 2, 2022

Caris, Sorrento, Prostate Cancer Clinical Trial Consortium Ink Clinical Trial Partnership

May 26, 2022

UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients
Premium

May 26, 2022

Mass General Hospital Gets Funding to Sequence Rare Melanoma Subtypes, Hunt for Novel Drug Targets
Premium